BALTIMORE, MD--(Marketwired - Aug 30, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that in a 2010 study at Canadian-based KGK Synergize, it was deduced that daily supplements of citrus limonoids and bioflavonoids may reduce factors for diabetes such as glucose tolerance. The findings were published in the Journal of Functional Foods. These results could serve as a solid foundation for the 2014 introduction of Plandai Biotechnology Inc.'s (
The Phytofare™ Limonoid Glycoside Complex could prove to a major benefit to diabetics, the elderly, and others that suffer from capillary and circulatory problems. The Limonoid Glycoside products are made lemons and utilize the entire fruit -- pith, peel, pulp and juice, to extract all soluble phytonutrients, including vitamins A & C, bioflavonoids, and variety of minerals including potassium and pectin.
The human trial portion of the aforementioned tests involved 19 subjects with impaired fasting glucose. The study found that the LDL cholesterol levels were lowered in 13 of the 19 test subjects, and more importantly, related to diabetes, a significant reduction in glucose intolerance was observed.
Diabetes has become a major health issue in the United States and other industrialized nations. According to the American Diabetes Association, nearly 24 million people in the United States, or 8% of the population, have either Type I or Type II diabetes. Additionally, according to the International Diabetes Federation (IDF), more than 370 million people have diabetes worldwide, with Type II accounting for 90-95% of all cases. Additionally, the IDF estimates that by 2030 about 550 million people could have the disease. Alternative and preventive measures like the supplements found in the Citrus Limonoid Glycoside Complex Phytofare™ products from Plandaí will be a key in stopping the proliferation of the diabetes epidemic.
Plandaí Biotechnology's key catalyst in product success is its bioavailability, or the level of absorption into the blood stream from the extracts. The Phytofare™ Limonoid Glycoside Complex product will offer substantially higher bioavailability compared to products currently on the market, which is a huge advantage for the Company. The rollout and associated aggressive marketing should pave the way for the Company to profit from the superior products that target what is unfortunately a large and ever-growing diabetes prevention market throughout the globe.
Goldman Small Cap Research articles, reports, and updates on Plandai as well as associated disclaimers and disclosures can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (